Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel.
von Figura
G
G
Department of Internal Medicine I, University of Ulm, Ulm, Germany.
Stephani
J
J
Wagner
M
M
Wegener
M
M
Wolf
C
C
Adler
G
G
Kulaksiz
H
H
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy*; D002760:Cholangiopancreatography, Endoscopic Retrograde; D015209:Cholangitis, Sclerosing / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D017239:Paclitaxel